Shashi Amur - Concepedia

Author

Shashi Amur

United States Food and Drug Administration

Also Known As

S Amur, S. Amur, Shashi Amur, Shashi G Amur, Steven Hoffmann

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research Biogen (United States)Bristol-Myers Squibb (United States)Pfizer (United States)

About

Shashi Amur is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	2.5K
2	Engineering	2	2	2.2K
3	Public Health	2	2	149
4	Health Sciences	1	1	15
5	Natural Sciences	1	1	65

Shashi Amur

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Leming Shi, Leming Shi, Laura Reid, Nature Biotechnology BioinformaticsSystems BiologyGene Expression MeasurementsEngineeringMedicine	2006	2.2K
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies Leming Shi, Wendell Jones, Roderick V. Jensen, BMC Bioinformatics	2008	400
Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use Felix W. Frueh, Shashi Amur, Padmaja Mummaneni, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2008	306
Integration and Use of Biomarkers in Drug Development, Regulation and Clinical Practice: a US Regulatory Perspective Shashi Amur, Felix W. Frueh, Lawrence J. Lesko, Biomarkers in Medicine Therapeutic AreaBiomarker (Medicine)Us FdaRegulatory ConsiderationBiomarker Discovery	2008	113
Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury Steven C. Hoffmann, Robert L. Kampen, Shashi Amur, Transplantation	2002	98
2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62) Steven P. Piccoli, Devangi Mehta, Alessandra Vitaliti, Bioanalysis	2019	92
2017 White Paper on Recent Issues in Bioanalysis: A Global Perspective on Immunogenicity Guidelines & Biomarker Assay Performance (Part 3 – Lba: Immunogenicity, Biomarkers and PK Assays) Shalini Gupta, Susan Richards, Lakshmi Amaravadi, Bioanalysis ImmunohematologyPk AssaysWhite PaperImmunologyBiological Mass Spectrometry	2017	65
Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement Ann Chen Wu, James P. Kiley, Patricia J. Noel, American Journal of Respiratory and Critical Care Medicine	2018	62
Building a Roadmap to Biomarker Qualification: Challenges and Opportunities Shashi Amur, Sarmistha Sanyal, Aloka Chakravarty, Biomarkers in Medicine PathologyBiomarker (Medicine)Translational MedicineBiomarker DiscoveryRegulatory Acceptance	2015	54
Allopurinol Pharmacogenetics: Assessment of Potential Clinical Usefulness Issam Zineh, Padmaja Mummaneni, Jenna Lyndly, Pharmacogenomics Drug SafetyAllopurinol Use DataHla VariationAllergyMedicine	2011	37

Page 1